1. Home
  2. CYCCP vs VGM Comparison

CYCCP vs VGM Comparison

Compare CYCCP & VGM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYCCP
  • VGM
  • Stock Information
  • Founded
  • CYCCP N/A
  • VGM 1992
  • Country
  • CYCCP United States
  • VGM United States
  • Employees
  • CYCCP 12
  • VGM N/A
  • Industry
  • CYCCP Biotechnology: Pharmaceutical Preparations
  • VGM Trusts Except Educational Religious and Charitable
  • Sector
  • CYCCP Health Care
  • VGM Finance
  • Exchange
  • CYCCP Nasdaq
  • VGM Nasdaq
  • Market Cap
  • CYCCP N/A
  • VGM N/A
  • IPO Year
  • CYCCP N/A
  • VGM N/A
  • Fundamental
  • Price
  • CYCCP $6.94
  • VGM $10.16
  • Analyst Decision
  • CYCCP
  • VGM
  • Analyst Count
  • CYCCP 0
  • VGM 0
  • Target Price
  • CYCCP N/A
  • VGM N/A
  • AVG Volume (30 Days)
  • CYCCP N/A
  • VGM 186.2K
  • Earning Date
  • CYCCP N/A
  • VGM 01-01-0001
  • Dividend Yield
  • CYCCP N/A
  • VGM 4.34%
  • EPS Growth
  • CYCCP N/A
  • VGM N/A
  • EPS
  • CYCCP N/A
  • VGM 0.01
  • Revenue
  • CYCCP N/A
  • VGM N/A
  • Revenue This Year
  • CYCCP N/A
  • VGM N/A
  • Revenue Next Year
  • CYCCP N/A
  • VGM N/A
  • P/E Ratio
  • CYCCP N/A
  • VGM $988.00
  • Revenue Growth
  • CYCCP N/A
  • VGM N/A
  • 52 Week Low
  • CYCCP N/A
  • VGM $8.15
  • 52 Week High
  • CYCCP N/A
  • VGM $10.07
  • Technical
  • Relative Strength Index (RSI)
  • CYCCP 50.02
  • VGM 44.27
  • Support Level
  • CYCCP $5.58
  • VGM $10.14
  • Resistance Level
  • CYCCP $7.07
  • VGM $10.30
  • Average True Range (ATR)
  • CYCCP 0.17
  • VGM 0.08
  • MACD
  • CYCCP 0.03
  • VGM 0.00
  • Stochastic Oscillator
  • CYCCP 70.83
  • VGM 36.92

About CYCCP Cyclacel Pharmaceuticals Inc.

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.

Share on Social Networks: